Silverarc Capital Management
Latest statistics and disclosures from Silverarc Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MRUS, NUVL, RNA, URGN, ERAS, and represent 30.75% of Silverarc Capital Management's stock portfolio.
- Added to shares of these 10 stocks: NUVL (+$23M), ERAS (+$18M), Insmed (+$17M), ITCI (+$11M), URGN (+$10M), ALNY (+$8.7M), SNDX (+$7.6M), ELUT (+$7.6M), SRPT (+$6.6M), CRBP (+$6.4M).
- Started 15 new stock positions in ENGN, CATX, ALNY, IRON, Insmed, SNDX, STOK, BHVN, LBPH, SLNO. Alx Oncology Hldgs, PCVX, SRPT, BDSX, TARS.
- Reduced shares in these 10 stocks: , Alpine Immune Sciences (-$7.9M), CRNX (-$6.0M), PRAX (-$5.1M), SLDB, BOLD, SRRK, CYTK, APGE, XENE.
- Sold out of its positions in ACET, Alpine Immune Sciences, AMLX, Amylyx Pharmaceuticals, APGE, BOLD, CRNX, CYTK, DXCM, IMNM. IsoRay, KRYS, Macrogenics, MLYS, PLRX, RZLT, RCKT, SRRK, TERN, VKTX, XENE, NAMS.
- Silverarc Capital Management was a net buyer of stock by $100M.
- Silverarc Capital Management has $424M in assets under management (AUM), dropping by 17.72%.
- Central Index Key (CIK): 0001816307
Tip: Access up to 7 years of quarterly data
Positions held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Silverarc Capital Management
Silverarc Capital Management holds 70 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Merus N V (MRUS) | 8.7 | $37M | +10% | 624k | 59.17 |
|
| Nuvalent Inc-a (NUVL) | 8.3 | $35M | +195% | 466k | 75.86 |
|
| Avidity Biosciences Ord (RNA) | 5.0 | $21M | +5% | 518k | 40.85 |
|
| Urogen Pharma (URGN) | 4.4 | $19M | +116% | 1.1M | 16.78 |
|
| Erasca (ERAS) | 4.4 | $18M | +3392% | 7.8M | 2.36 |
|
| Insmed Call Call Option | 4.0 | $17M | NEW | 250k | 67.00 |
|
| Morphic Hldg (MORF) | 3.9 | $17M | 486k | 34.07 |
|
|
| Akero Therapeutics (AKRO) | 3.5 | $15M | +56% | 625k | 23.46 |
|
| Celldex Therapeutics Com New (CLDX) | 3.3 | $14M | +25% | 375k | 37.01 |
|
| Intra Cellular Therapies (ITCI) | 3.1 | $13M | +452% | 192k | 68.49 |
|
| Poseida Therapeutics I (PSTX) | 2.5 | $11M | 3.6M | 2.92 |
|
|
| Cogent Biosciences (COGT) | 2.4 | $10M | +16% | 1.2M | 8.43 |
|
| Insmed Com Par $.01 (INSM) | 2.2 | $9.4M | +23% | 140k | 67.00 |
|
| Alnylam Pharmaceuticals (ALNY) | 2.1 | $8.7M | NEW | 36k | 243.00 |
|
| Elutia Cl A Com (ELUT) | 1.9 | $8.0M | +1940% | 1.6M | 4.96 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.8 | $7.8M | +439% | 173k | 45.25 |
|
| Oric Pharmaceuticals (ORIC) | 1.8 | $7.6M | -3% | 1.1M | 7.07 |
|
| Syndax Pharmaceuticals (SNDX) | 1.8 | $7.6M | NEW | 370k | 20.53 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.8 | $7.6M | 185k | 41.06 |
|
|
| C4 Therapeutics Com Stk (CCCC) | 1.6 | $6.7M | 1.4M | 4.62 |
|
|
| Sarepta Therapeutics (SRPT) | 1.6 | $6.6M | NEW | 42k | 158.00 |
|
| Kalvista Pharmaceuticals (KALV) | 1.6 | $6.6M | 561k | 11.78 |
|
|
| Veracyte (VCYT) | 1.4 | $6.1M | 282k | 21.67 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 1.4 | $6.0M | +507% | 456k | 13.22 |
|
| Olema Pharmaceuticals (OLMA) | 1.4 | $5.9M | +6% | 547k | 10.82 |
|
| Adc Therapeutics Sa SHS (ADCT) | 1.3 | $5.6M | +252% | 1.8M | 3.16 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 1.2 | $5.1M | 500k | 10.22 |
|
|
| Mersana Therapeutics (MRSN) | 1.2 | $5.0M | -15% | 2.5M | 2.01 |
|
| Gossamer Bio (GOSS) | 1.2 | $5.0M | -10% | 5.5M | 0.90 |
|
| Tela Bio (TELA) | 1.1 | $4.7M | +28% | 1.0M | 4.70 |
|
| Disc Medicine (IRON) | 1.1 | $4.6M | NEW | 101k | 45.07 |
|
| Biogen Idec (BIIB) | 1.1 | $4.5M | 19k | 231.82 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 1.0 | $4.4M | +122% | 305k | 14.46 |
|
| Geron Corporation (GERN) | 1.0 | $4.2M | +299% | 999k | 4.24 |
|
| Biohaven (BHVN) | 0.8 | $3.5M | NEW | 100k | 34.71 |
|
| Longboard Pharmaceuticals In (LBPH) | 0.8 | $3.3M | NEW | 123k | 27.03 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.7 | $2.8M | -64% | 67k | 41.36 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.7 | $2.8M | +605% | 71k | 39.27 |
|
| Biodesix (BDSX) | 0.7 | $2.8M | NEW | 1.8M | 1.53 |
|
| Mirum Pharmaceuticals (MIRM) | 0.6 | $2.7M | 79k | 34.19 |
|
|
| Solid Biosciences Com New (SLDB) | 0.6 | $2.7M | -64% | 473k | 5.67 |
|
| Perspective Therapeutics Com New (CATX) | 0.6 | $2.6M | NEW | 260k | 9.97 |
|
| Cerus Corporation (CERS) | 0.6 | $2.6M | 1.5M | 1.76 |
|
|
| Compugen Ord (CGEN) | 0.6 | $2.5M | +50% | 1.5M | 1.68 |
|
| Trevi Therapeutics (TRVI) | 0.6 | $2.5M | 844k | 2.98 |
|
|
| Kodiak Sciences (KOD) | 0.6 | $2.5M | -14% | 1.1M | 2.35 |
|
| Jasper Therapeutics Com New (JSPR) | 0.6 | $2.5M | 110k | 22.70 |
|
|
| Engene Holdings (ENGN) | 0.6 | $2.5M | NEW | 264k | 9.43 |
|
| Wave Life Sciences SHS (WVE) | 0.6 | $2.5M | 496k | 4.99 |
|
|
| Fulcrum Therapeutics (FULC) | 0.6 | $2.5M | 398k | 6.20 |
|
|
| Evogene SHS (EVGN) | 0.5 | $2.0M | 3.1M | 0.65 |
|
|
| Stoke Therapeutics (STOK) | 0.5 | $1.9M | NEW | 142k | 13.51 |
|
| Macrogenics (MGNX) | 0.4 | $1.6M | -22% | 370k | 4.25 |
|
| Modular Med Com New (MODD) | 0.3 | $1.4M | 900k | 1.58 |
|
|
| Zura Bio Class A Ord Shs (ZURA) | 0.3 | $1.1M | 329k | 3.50 |
|
|
| Tarsus Pharmaceuticals (TARS) | 0.3 | $1.1M | NEW | 40k | 27.18 |
|
| Alx Oncology Hldgs Put Put Option | 0.2 | $1.0M | NEW | 168k | 6.03 |
|
| Vyne Therapeutics (VYNE) | 0.2 | $921k | +441% | 467k | 1.97 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.2 | $870k | -59% | 100k | 8.70 |
|
| 89bio (ETNB) | 0.2 | $739k | 92k | 8.01 |
|
|
| Molecular Templates Com New (MTEM) | 0.2 | $717k | +75% | 624k | 1.15 |
|
| Fractyl Health (GUTS) | 0.2 | $712k | 167k | 4.27 |
|
|
| C4 Therapeutics Call Call Option | 0.2 | $693k | 150k | 4.62 |
|
|
| Soleno Therapeutics (SLNO) | 0.1 | $612k | NEW | 15k | 40.80 |
|
| Karyopharm Therapeutics (KPTI) | 0.1 | $485k | 559k | 0.87 |
|
|
| Mersana Therapeutics Call Call Option | 0.1 | $338k | +9800% | 168k | 2.01 |
|
| Relmada Therapeutics (RLMD) | 0.1 | $298k | 99k | 3.00 |
|
|
| Aligos Therapeutics (ALGS) | 0.1 | $229k | 656k | 0.35 |
|
|
| Vaxcyte (PCVX) | 0.0 | $189k | NEW | 2.5k | 75.51 |
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $6.4k | 105k | 0.06 |
|
Past Filings by Silverarc Capital Management
SEC 13F filings are viewable for Silverarc Capital Management going back to 2020
- Silverarc Capital Management 2024 Q2 filed Aug. 14, 2024
- Silverarc Capital Management 2024 Q1 filed May 15, 2024
- Silverarc Capital Management 2023 Q4 filed Feb. 14, 2024
- Silverarc Capital Management 2023 Q3 filed Nov. 13, 2023
- Silverarc Capital Management 2023 Q2 filed Aug. 14, 2023
- Silverarc Capital Management 2023 Q1 filed May 15, 2023
- Silverarc Capital Management 2022 Q4 filed Feb. 14, 2023
- Silverarc Capital Management 2022 Q3 filed Oct. 28, 2022
- Silverarc Capital Management 2022 Q2 filed July 25, 2022
- Silverarc Capital Management 2022 Q1 filed May 13, 2022
- Silverarc Capital Management 2021 Q4 filed Feb. 14, 2022
- Silverarc Capital Management 2021 Q3 filed Nov. 15, 2021
- Silverarc Capital Management 2021 Q2 filed Aug. 16, 2021
- Silverarc Capital Management 2021 Q1 filed May 18, 2021
- Silverarc Capital Management 2020 Q4 filed Feb. 16, 2021